Table 3.
Variables associated with risk of all-cause mortalitya
| Variable | Univariable analysis | Multivariable analysis | ||
|---|---|---|---|---|
|
| ||||
| Median, mo (95% CI) | P | HR (95% CI) | P | |
| Age group, y | < .001 | |||
| 67-75 | 28 (26-29) | Reference | ||
| 76-84 | 18 (17-19) | 1.36 (1.30-1.41) | < .001 | |
| ≥ 85 | 7 (6-8) | 2.32 (2.20-2.46) | < .001 | |
| Sex | ||||
| Men | 18 (17-19) | Reference | ||
| Women | 19 (18-20) | .049 | 0.91 (0.88-0.94) | < .001 |
| Race | ||||
| White | 19 (45-48) | Reference | ||
| Black | 17 (16-19) | < .001 | 0.93 (0.87-0.99) | .026 |
| Other | 23 (20-26) | 0.97 (0.86-1.09) | .605 | |
| Unknown | 125 (55-125) | 0.28 (0.18-0.45) | < .001 | |
| Ethnicity | .436 | Not significant | ||
| Non-Hispanic | 19 (18-19) | |||
| Hispanic | 18 (16-21) | |||
| Residence | .018 | Not significant | ||
| Large metropolitan | 19 (18-20) | |||
| Metropolitan | 20 (18-21) | |||
| Urban | 19 (17-22) | |||
| Less urban | 17 (14-19) | |||
| Rural | 16 (11-20) | |||
| Median annual household income | ||||
| ≤ $25,000 | 16 (14-17) | Reference | ||
| $25,001-$45,000 | 17 (16-18) | 0.96 (0.90-1.03) | .259 | |
| $45,001-$65,000 | 20 (19-22) | < .001 | 0.87 (0.80-0.93) | < .001 |
| $65,001-$85,000 | 21 (19-23) | 0.85 (0.78-0.93) | < .001 | |
| > $85,000 | 25 (22-28) | 0.77 (0.70-0.86) | < .001 | |
| Not available | 20 (12-24) | 0.94 (0.75-1.17) | .552 | |
| Comorbidity score | ||||
| 0 | 23 (22-24) | Reference | ||
| 1 | 15 (13-17) | < .001 | 1.21 (1.15-1.27) | < .001 |
| 2 | 10 (8-11) | 1.50 (1.40-1.61) | < .001 | |
| ≥3 | 7 (6-8) | 1.85 (1.71-1.99) | < .001 | |
| Cancer type | ||||
| Multiple myeloma | 17 (17-18) | Reference | ||
| Lymphoplasmacytic lymphoma | 41 (34-49) | < .001 | 0.49 (0.44-0.54) | < .001 |
| Waldenström macroglobulinemia | 42 (38-48) | 0.54 (0.49-0.59) | < .001 | |
| Year of diagnosis | ||||
| 1994-1999 | 19 (18-20) | Reference | ||
| 2000-2005 | 19 (18-20) | .006 | 0.94 (0.90-0.98) | .003 |
| SEER site | ||||
| California | 18 (17-19) | Reference | ||
| Atlanta | 14 (13-18) | 1.11 (1.01-1.23) | .037 | |
| Connecticut | 21 (18-24) | 0.96 (0.90-1.04) | .319 | |
| Detroit | 17 (15-18) | 1.04 (0.98-1.11) | .233 | |
| Hawaii | 26 (18-31) | 0.93 (0.77-1.12) | .429 | |
| Iowa | 20 (18-22) | 0.93 (0.86-0.99) | .034 | |
| Kentucky | 15 (13-19) | < .001 | 1.01 (0.92-1.11) | .786 |
| Louisiana | 18 (14-21) | 0.95 (0.87-1.05) | .325 | |
| New Jersey | 19 (17-21) | 0.97 (0.90-1.04) | .319 | |
| New Mexico | 20 (17-25) | 0.94 (0.84-1.07) | .350 | |
| Rural Georgia | 12 (7-17) | 1.15 (0.84-1.58) | .382 | |
| Seattle | 24 (21-26) | 0.89 (0.83-0.97) | .004 | |
| Utah | 17 (13-23) | 1.03 (0.93-1.14) | .626 | |
| MGUS follow-up | ||||
| No | 19 (18-19) | Reference | ||
| Yes | 23 (20-27) | < .001 | 0.87 (0.80-0.95) | < .001 |
Abbreviations: CI = confidence interval; HR = hazard ratio; SEER = Surveillance, Epidemiology, and End Results; MGUS = monoclonal gammopathy of undetermined significance.
a
All statistical tests were two-sided.